<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626522</url>
  </required_header>
  <id_info>
    <org_study_id>M/273FO/23</org_study_id>
    <secondary_id>2007-004435-30</secondary_id>
    <nct_id>NCT00626522</nct_id>
  </id_info>
  <brief_title>Aclidinium/Formoterol Fixed Combination Dose Finding Study</brief_title>
  <official_title>A Randomised, 4-week, Placebo-controlled, Double-blind, 6 Arm Parallel Group, Dose-finding Clinical Trial, to Assess the Efficacy, Safety and Pharmacokinetics of Three Different Doses of Formoterol Combined With the Inhaled Anticholinergic Aclidinium Bromide, Aclidinium Bromide Monotherapy and Formoterol Monotherapy All Administrated Once Daily by Inhalation Via Almirall Inhaler in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for
      investigation in Phase III clinical trials
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose-finding clinical trial, to assess the efficacy, safety and pharmacokinetics of three
      different doses of formoterol combined with the inhaled anticholinergic aclidinium bromide,
      aclidinium bromide monotherapy and formoterol monotherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr</measure>
    <time_frame>Baseline and treatment Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and treatment Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and treatment Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-3 hr</measure>
    <time_frame>Baseline and treatment Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-6 hr</measure>
    <time_frame>Baseline and treatment Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">808</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide and formoterol</intervention_name>
    <description>once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide and formoterol placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males or non-pregnant, non-lactating females aged between 40 and 80 years old,
             both inclusive. Women of childbearing potential were allowed to enter the trial only
             if they used two medically approved contraceptive measures (ie, mechanical and
             pharmacological).

             (A female was considered to be of childbearing potential unless she had a
             hysterectomy, was at least one year post-menopause or had undergone tubal ligation.
             All women of childbearing potential were to have a negative serum pregnancy test at
             the Screening Visit).

          2. Patients with a clinical diagnosis of stable moderate to severe COPD (stages II and
             III) according to the GOLD 2006 classification (http://www.goldcopd.com).

          3. Current or ex-cigarette smoker with a smoking history of at least 10 pack-years.

             Pack-years were calculated by dividing the number of cigarettes smoked per day by 20
             (the number of cigarettes in a pack) and multiplying this figure by the number of
             years a person had smoked. For example, a person who smoked 40 cigarettes a day and
             had smoked for 10 years would have had a 20 pack-year smoking history (40 cigarettes
             per day ÷ 20 cigarettes per pack = 2; 2 x 10 years of smoking = 20 pack-year history).

             Patients smoking other tobacco types were not allowed, unless they met the cigarette
             criterion as well.

          4. Patients whose Forced Expiratory Volume in 1 second (FEV1) at the Screening Visit
             measured between 30-45 minutes post inhalation of 400 μg of salbutamol was 30% ≤FEV1
             &lt;80% of the predicted normal value (ie, 100 x Post-salbutamol FEV1/Predicted FEV1 &lt;80%
             and ≥30%). (Predicted normal values used for calculation purposes were to be based on
             European Community for Steel and Coal predicted values)

          5. Patients whose FEV1/Forced Vital Capacity (FVC) at the Screening Visit measured
             between 30- 45 minutes post inhalation of 400 μg of salbutamol was &lt;70% (ie, 100 x
             Post-salbutamol FEV1/FVC &lt;70%).

          6. Patients whose COPD symptoms and FEV1 values at the time of randomisation were stable
             compared to the Screening Visit, according to the Investigator's medical judgment.

          7. Patients who were eligible and able to participate in the trial and who consented to
             do so in writing after the purpose and nature of the investigation had been explained.

        Exclusion Criteria:

          1. History or current diagnosis of asthma, allergic rhinitis or atopy, or
             exercise-induced bronchospasm.

          2. Eosinophil count ≥600 cells/mm3.

          3. Clinically significant respiratory conditions at the time of Screening Visit defined
             as:

               -  Use of long-term oxygen therapy &gt;5 h/day,

               -  Known active tuberculosis,

               -  History of interstitial lung or pulmonary thromboembolic disease,

               -  Pulmonary resection during the past 12 months,

               -  History of life-threatening COPD,

               -  History of bronchiectasis secondary to respiratory diseases others than COPD (eg,
                  cystic fibrosis, Kartagener's syndrome, etc),

               -  Patients who in the Investigator's opinion may have needed to stop or start
                  pulmonary rehabilitation or undergo a thoracotomy during the trial,

          4. Hospitalisation due to COPD exacerbation, up to the 3 months prior to the Screening
             Visit.

          5. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory
             tract), up to the 6 weeks prior to the Screening Visit.

          6. Clinically significant cardiovascular conditions at the time of Screening Visit
             defined as:

               -  Myocardial infarction within the previous 6 months,

               -  Unstable arrhythmia which has required changes in the pharmacological therapy or
                  other intervention within the previous 12 months, or newly diagnosed arrhythmia
                  within the previous 3 months.

               -  Hospitalisation within the previous 12 months for heart failure functional
                  classes III (marked limitation of activity and only comfortable at rest) and IV
                  (need of complete rest, confinement to bed or chair, discomfort at any physical
                  activity and presence of symptoms at rest) as per the New York Heart Association
                  classification (www.americanheart.org)

               -  Thoracic surgery within the previous 24 months

          7. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.
             (However, patients who had a diagnosis of these conditions but without symptoms due to
             stable concomitant medication for its treatment were allowed to enter trial).

          8. Presence of narrow-angle glaucoma.

          9. History of untoward reactions or known hypersensitivity to inhaled anticholinergics
             (including aclidinium bromide), β2 adrenergic agonists or inhaled medication or any
             component thereof (including report of paradoxical bronchospasm).

         10. Life expectancy of less than 1 year.

         11. Prolonged QT interval corrected using Bazett's formula (QTcB) interval (&gt;470 msec) in
             any of the ECGs performed before randomisation, and/or the use of drugs which may have
             induced its prolongation.

         12. Clinically relevant abnormalities in laboratory results, ECG parameters (other than
             QTcB), or physical examination if the abnormality defines a disease state listed as an
             exclusion criterion, except for those related to COPD.

         13. Clinically significant diseases other than COPD, which, in the opinion of the
             Investigator, may have put the patient at risk because of the participation in the
             trial; or diseases which may have influenced the results of the study or the patient's
             ability to take part in it.

         14. Patients who did not maintain regular day/night, waking/sleeping cycles (eg, night
             shift workers were to be excluded).

         15. Patients who intended to use any concomitant medication not permitted by the protocol
             or who had not undergone the required wash-out period for a particular prohibited
             medication.

         16. Patients who were unable or unlikely to be cooperative with the study requirements of
             taking the medication, completion of the Patient Diary and attending the clinic for
             study visits.

         17. Patients who were unable to properly use a dry powder or pressurised metered-dose
             inhalers (pMDI) inhaler device and/or to perform acceptable and reproducible
             spirometry measurements as per the ATS/ERS standards (Standardisation of lung function
             test, 2005 20).

         18. History of drug and/or alcohol abuse or addiction during the previous 2 years.

         19. Previous participation in another clinical trial with any investigational medicinal
             product 6 weeks prior to the Screening Visit. (Patients who had participated in a
             previous clinical trial with aclidinium bromide (Almirall product code LAS34273) were
             to be allowed to participate in this study provided that the above criterion was
             fulfilled. This circumstance was to be specifically recorded on the eCRF).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St-Petersburg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Sponsor website</description>
  </link>
  <link>
    <url>http://www.frx.com/</url>
    <description>Co-Sponsor website</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3953&amp;filename=Synopsis-m-273FO-23-Final.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>June 28, 2016</results_first_submitted>
  <results_first_submitted_qc>June 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2016</results_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchitis</keyword>
  <keyword>Chronic</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Smokers or ex-Smokers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in a total of 81 sites: 21 in Russia, 13 in Poland, 8 in India, 8 in Romania, 6 in Australia, 5 in Taiwan, 5 in the Czech Republic, 5 in New Zealand, 4 in Hungary, 3 in Malaysia and 3 in Slovakia
The first patient was screened in February 2008 and the last patient visit was in November 2008</recruitment_details>
      <pre_assignment_details>A total of 808 patients were screened and 566 were randomized into the study
Among 242 patients who failed to be randomized, the main reason for screen failure was non-fulfillment of one or more study entry criteria (156 patients), followed by subject’s personal request (32 patients)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aclidinium 200 μg / Formoterol 6 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="P2">
          <title>Aclidinium 200 μg / Formoterol 12 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="P3">
          <title>Aclidinium 200 μg / Formoterol 18 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="P4">
          <title>Aclidinium 200 μg</title>
          <description>Aclidinium bromide 200 μg once-daily</description>
        </group>
        <group group_id="P5">
          <title>Formoterol 12 μg</title>
          <description>Formoterol fumarate 12 μg once-daily</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo once-daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="58"/>
                <participants group_id="P6" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COPD exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inconsistent reason reported</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-fulfilment of in/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aclidinium 200 μg / Formoterol 6 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="B2">
          <title>Aclidinium 200 μg / Formoterol 12 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="B3">
          <title>Aclidinium 200 μg / Formoterol 18 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="B4">
          <title>Aclidinium 200 μg</title>
          <description>Aclidinium bromide 200 μg once-daily</description>
        </group>
        <group group_id="B5">
          <title>Formoterol 12 μg</title>
          <description>Formoterol fumarate 12 μg once-daily</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo once-daily</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="125"/>
            <count group_id="B4" value="76"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="59"/>
            <count group_id="B7" value="566"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="9.0"/>
                    <measurement group_id="B2" value="63.6" spread="8.9"/>
                    <measurement group_id="B3" value="63.9" spread="8.1"/>
                    <measurement group_id="B4" value="63.7" spread="9.3"/>
                    <measurement group_id="B5" value="64.0" spread="9.8"/>
                    <measurement group_id="B6" value="60.7" spread="7.8"/>
                    <measurement group_id="B7" value="63.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr</title>
        <time_frame>Baseline and treatment Week 4</time_frame>
        <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 18 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg once-daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg once-daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr</title>
          <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.170" lower_limit="0.128" upper_limit="0.213"/>
                    <measurement group_id="O2" value="0.219" lower_limit="0.176" upper_limit="0.262"/>
                    <measurement group_id="O3" value="0.230" lower_limit="0.187" upper_limit="0.273"/>
                    <measurement group_id="O4" value="0.075" lower_limit="0.021" upper_limit="0.129"/>
                    <measurement group_id="O5" value="0.099" lower_limit="0.037" upper_limit="0.161"/>
                    <measurement group_id="O6" value="-0.036" lower_limit="-0.097" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.206</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.131</ci_lower_limit>
            <ci_upper_limit>0.280</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.254</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.180</ci_lower_limit>
            <ci_upper_limit>0.329</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.191</ci_lower_limit>
            <ci_upper_limit>0.340</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Baseline and treatment Week 4</time_frame>
        <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 18 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg once-daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg once-daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042" lower_limit="0.001" upper_limit="0.084"/>
                    <measurement group_id="O2" value="0.085" lower_limit="0.044" upper_limit="0.127"/>
                    <measurement group_id="O3" value="0.044" lower_limit="0.003" upper_limit="0.085"/>
                    <measurement group_id="O4" value="-0.017" lower_limit="-0.70" upper_limit="0.036"/>
                    <measurement group_id="O5" value="0.014" lower_limit="-0.043" upper_limit="0.071"/>
                    <measurement group_id="O6" value="-0.031" lower_limit="-0.091" upper_limit="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Baseline and treatment Week 4</time_frame>
        <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 18 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg once-daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg once-daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.294" lower_limit="0.250" upper_limit="0.338"/>
                    <measurement group_id="O2" value="0.357" lower_limit="0.313" upper_limit="0.401"/>
                    <measurement group_id="O3" value="0.349" lower_limit="0.305" upper_limit="0.393"/>
                    <measurement group_id="O4" value="0.184" lower_limit="0.128" upper_limit="0.240"/>
                    <measurement group_id="O5" value="0.216" lower_limit="0.156" upper_limit="0.276"/>
                    <measurement group_id="O6" value="0.044" lower_limit="-0.019" upper_limit="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-3 hr</title>
        <time_frame>Baseline and treatment Week 4</time_frame>
        <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 18 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg once-daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg once-daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-3 hr</title>
          <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" lower_limit="0.158" upper_limit="0.236"/>
                    <measurement group_id="O2" value="0.256" lower_limit="0.217" upper_limit="0.295"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.211" upper_limit="0.289"/>
                    <measurement group_id="O4" value="0.088" lower_limit="0.038" upper_limit="0.138"/>
                    <measurement group_id="O5" value="0.134" lower_limit="0.081" upper_limit="0.188"/>
                    <measurement group_id="O6" value="-0.033" lower_limit="-0.091" upper_limit="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-6 hr</title>
        <time_frame>Baseline and treatment Week 4</time_frame>
        <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 18 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg once-daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg once-daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo once-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-6 hr</title>
          <population>ITT Population defined as all randomised patients who took at least one dose of investigational medicinal product and had at least the baseline and one post-baseline efficacy assessments</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" lower_limit="0.164" upper_limit="0.249"/>
                    <measurement group_id="O2" value="0.266" lower_limit="0.223" upper_limit="0.309"/>
                    <measurement group_id="O3" value="0.272" lower_limit="0.229" upper_limit="0.314"/>
                    <measurement group_id="O4" value="0.094" lower_limit="0.040" upper_limit="0.148"/>
                    <measurement group_id="O5" value="0.137" lower_limit="0.076" upper_limit="0.198"/>
                    <measurement group_id="O6" value="-0.033" lower_limit="-0.094" upper_limit="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 38</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aclidinium 200 μg / Formoterol 6 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="E2">
          <title>Aclidinium 200 μg / Formoterol 12 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="E3">
          <title>Aclidinium 200 μg / Formoterol 18 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumarate 18 μg fixed dose combination (FDC) once-daily</description>
        </group>
        <group group_id="E4">
          <title>Aclidinium 200 μg</title>
          <description>Aclidinium bromide 200 μg once-daily</description>
        </group>
        <group group_id="E5">
          <title>Formoterol 12 μg</title>
          <description>Formoterol fumarate 12 μg once-daily</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo once-daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication and/or presentation whether complete or partial, of any part of the data or results of this trial, will be subject to revision and written agreement between the investigator and sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Esther Garcia</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

